ACUMEN PHARMACEUTICALS INC (ABOS)
Health Care · Alzheimer's disease / neurodegeneration therapeutics · NASDAQ
Clinical-stage biotech developing sabirnetug, a monoclonal antibody that targets amyloid-beta oligomers to modify disease progression in Alzheimer's patients, with Phase 2 results expected in late 2026.
What ACUMEN PHARMACEUTICALS INC does
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting amyloid-beta oligomers (AßOs), which are believed to be a primary driver of Alzheimer's disease pathology. The company's lead product candidate, sabirnetug (ACU193), is a humanized monoclonal antibody currently in Phase 2 clinical trials (ALTITUDE-AD) designed to selectively target and neutralize AßOs. Acumen is also developing an Enhanced Brain Delivery (EBD) technology platform in collaboration with JCR Pharmaceuticals to create blood-brain barrier-penetrating therapies for Alzheimer's disease and potentially other neurodegenerative conditions.
Themes: Alzheimer's disease / neurodegeneration, Amyloid-beta targeting, Monoclonal antibody therapeutics, Immunotherapy, CNS drug delivery
Fundamentals
- Price$3.16 as of 2026-08-21 close
- Market cap$229M as of 2026-08-21
- 1-year return+132.4% 2025-08-21 close $1.36 → 2026-08-21 close $3.16
- P/En/a negative earnings
- Net margin-509.7% as of 2026-08-24
- ROE-123.1% as of 2026-08-24
- Debt / equity0.35 as of 2026-08-24
- Beta0.31 as of 2026-08-24
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How ABOS compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ACUMEN PHARMACEUTICALS INC looks technically
ACUMEN PHARMACEUTICALS INC (ABOS) is trading 32.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 235 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 35, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 78, in overbought territory (above 70). It made a new 20-day high about 2 trading days ago.
Trend
9
| Distance from the 200-day | it is trading 32.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +32.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.44 | $2.44 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.38 | $2.38 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 23 calendar days ago — the swings before that are what the structure reading is measured on | 23 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 2.095. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 235 trading days ago — a "golden cross", a bullish long-term signal | 235 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 32.5% above | +32.5% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 35, with buyers in control | 34.5 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 78, in overbought territory (above 70) | 77.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($2.18 to $3.34) — its "stochastic" reading is 84 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 84.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $3.60 | $3.60 |
|---|---|---|
| From the 52-week high | it is 12.2% below its 52-week high (its highest price of the past year) | -12.2% |
| Above the 52-week low | it is 161.2% above its 52-week low (its lowest price of the past year) | +161.2% |
| Below the 52-week high | it is 12.2% below its highest point of the past year | 12.2% |
| Since a 20-day breakout | it made a new 20-day high about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $11.31 (set on 2023-07-17) | $11.31 |
| Given back of the 52-week move | over the past year its closes ranged ($1.23 to $3.37), and it has given back only a small part of its rise from last year’s low — 10% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.98 to $2.05. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 9.8% |
| From the all-time high | it is 72.1% below its all-time high | -72.1% |
| Nearest price level | it is trading 10.7% above a support level at $2.82 — a price it turned at three times since 2026-04-06, most recently on 2026-07-09. Since 2024-08-21 it has 13 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -10.7% |
| All-time low | its lowest closing price on record is $0.8551 (set on 2025-04-21) | $0.8551 |
| Above the all-time low | it is 269.5% above its all-time low | +269.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 98% of the past ~6 months) | 98th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1731 between its high and its low — about 5.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1731 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.82 and $3.16 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.82 – $2.49 – $3.16 |
| Typical daily range (% of price) | its price moves about 5.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.5% |
| Stretch from the 200-day average | it is trading 4.5 daily ranges above its 200-day average price (32.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.89× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.6% |
|---|---|---|
| Gap filled | a 2.4% gap down opened on 2026-08-12 has been "filled" 7 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 7 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 39.4 percentage points (the stock gained 41.7% while the market gained 2.3%) | +39.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 23.8 percentage points (the stock gained 26.9% while the market gained 3.1%) | +23.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 11.9 percentage points (the stock gained 23.0% while the market gained 11.1%) | +11.9% |
| vs market, 12 months | over the past 12 months this stock beat the market by 111.9 percentage points (the stock gained 132.4% while the market gained 20.5%) | +111.9% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 28% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 0.5% of the share price, which is taken to mean a barrier that gives way easily. | +27.9% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 23% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $2.57 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +23.0% |
|---|
Price levels it has turned at before
ABOS last closed at $3.16 on 2026-08-21. Since 2024-08-21 it has turned at 13 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.82 | Support | 10.7% below the last close | turned there three times · 2026-04-06 to 2026-07-09 |
| $2.66 | Support | 15.8% below the last close | turned there twice · 2024-09-19 to 2026-06-01 |
| $2.46 | Support | 22.1% below the last close | turned there three times · 2024-11-25 to 2026-04-13 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $2.10.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$7.40 range $4.00 – $10.00; median $8.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ABOS
- Consensus EPS estimate-$0.3787 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Sabirnetug is still in Phase 2 development; ALTITUDE-AD top-line results are expected in late 2026, with substantial risk of failure to meet primary endpoints or demonstrate adequate safety/efficacy in a larger patient population","Dependence on third-party manufacturers and clinical trial vendors; inability to secure manufacturing capacity or contract research organization performance could delay development timelines","Significant cash burn and unprofitability (-509.72% net margin); reliance on future funding to advance sabirnetug and the EBD program, with substantial going-concern risk if funding cannot be secured"]
What changed in the latest 10-Q
AI-assisted comparison of ABOS's 10-Q filed 2026-05-12 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to audited financial statements and MD&A 'as of and for the year ended December 31, 2025' (newer) vs. 'December 31, 2024' (older)
- New sentence: 'We plan to announce top-line results in late 2026. Top-line results are expected to include the difference after 18 months as measured by the Integrated Alzheimer's Disease Rating Scale, or iADRS, our primary clinical efficacy endpoint, as well as key secondary endpoints, such as Clinical Dementia Rating – Sum of the Boxes, or CDR-SB, certain safety measures such as adverse event rates, including amyloid-related imaging abnormalities, or ARIA rates, and key biomarkers.'
- New paragraph beginning 'In addition, we are investigating a blood-brain barrier-penetrating...' with March 2026 preclinical data announcement and specific EBD candidate performance metrics (14-40x higher brain levels, hematology data, stability profile)
- New text: 'Based on this data, an investigational new drug, or IND, application is targeted for mid-2027.'
- New text: 'We currently anticipate that we will exercise our option to license two compounds developed as part of our collaboration with JCR during the second quarter of 2026.'
- Addition of clause 'for the treatment of AD' after 'EBD therapy' reference in collaboration agreement section
- Removed:
- Sentence: 'We completed enrollment in March 2025 and expect to announce top-line results for ALTITUDE-AD in late 2026.'
- Phrase: 'We plan to use the Integrated Alzheimer's Disease Rating Scale at 18 months as the primary outcome measure.' (replaced with more detailed description)
- Sentence: 'Our option can be exercised when there is a preclinical candidate data package, inclusive of a non-human primate study, which is expected in early 2026.'
- Phrase: 'for AD' appears once in older text but expanded in newer text with more specificity
- Text about first tranche borrowing and warrant issuance details (K2HV agreement specifics)
- Text about ATM offering program activity during nine months ended September 30, 2025
- Comparative net loss figures and research and development spending percentages
- Reworded:
- Changed 'targeting what we believe to be' to 'targeting what we believe to be' (stylistic consistency maintained)
- Changed 'Integrated Alzheimer's Disease Rating Scale' from full form to abbreviation 'iADRS' in primary endpoint description (newer provides more explicit clinical measurement details)
- Restructured JCR collaboration description: removed 'when there is a preclinical candidate data package' condition and replaced with 'We currently anticipate that we will exercise our option...during the second quarter of 2026'
- Notes:
- Text is truncated at loan agreement section in newer filing; full comparison of loan facility details cannot be completed
- Text is truncated at accumulated losses section in older filing; net loss figures and ATM activity details cannot be fully compared for all content
- The newer filing contains substantially more detail on EBD program preclinical results and IND timeline, while older filing only mentioned investigation of the therapy
Risk Factors
- Added:
- Added reference to 'any Aß oligomer-targeted Enhanced Brain Delivery (EBD™) product candidates that we may develop pursuant to our collaboration with JCR Pharmaceuticals Co. Ltd.' in forward-looking statements (filed 2026-05-12)
- Added phrase 'or any other product candidates we may develop' regarding reliance on third parties for preclinical trials (filed 2026-05-12)
- Added phrase 'or any other product candidates we may develop' regarding intellectual property scope of protection (filed 2026-05-12)
- Updated Annual Report reference from 'fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (the "SEC") on March 27, 2025' to 'fiscal year ended December 31, 2025, as filed with the Securities and Exchange Commission (the "SEC") on March 26, 2026' (filed 2026-05-12)
- Removed:
- Removed separate forward-looking statement bullet point 'the therapeutic potential of an oligomer-targeted Enhanced Brain Delivery (EBD™) therapy for Alzheimer's disease' (filed 2025-11-12)
- Removed reference to reliance on third parties specifically 'to conduct clinical trials of sabirnetug and manufacture sabirnetug for nonclinical studies and clinical trials' - replaced with expanded language (filed 2025-11-12)
- Reworded:
- Changed 'our plans relating to commercializing sabirnetug' to 'our plans relating to commercializing sabirnetug or any other product candidates that we may advance into clinical trials' (filed 2026-05-12)
- Changed 'our plans relating to the further development and manufacturing of sabirnetug' to 'our plans relating to the further development and manufacturing of sabirnetug and any other product candidates we may develop' (filed 2026-05-12)
- Changed 'data market exclusivity' to 'data and market exclusivity' (filed 2026-05-12)
- Changed 'the scope of protection we are able to establish and maintain for intellectual property rights covering sabirnetug and our technology' to include 'any other product candidates we may develop' (filed 2026-05-12)
- Merged two separate bullet points about sabirnetug funding and EBD therapy into single consolidated bullet about 'sabirnetug or any Aß oligomer-targeted Enhanced Brain Delivery (EBD™) product candidates' (filed 2026-05-12)
- Notes:
- The financial statements section shows different reporting periods (March 31, 2026 vs. September 30, 2025 and December 31, 2025 vs. December 31, 2024), so direct financial comparison is not assessable in this excerpt
- The table of contents page numbers differ (31 vs. 33 for Risk Factors and subsequent items), which is expected given content changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 4 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 4 sells ($89512) — 2 selling insiders
- Last 180 days0 buys · 5 sells ($96326) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-17. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ABOS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ABOS as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 1,973,346
- Reported value $4,657,097
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ABOS had 3,367,011 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ABOS had 4.66% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.46 days to cover at the same settlement.
- Reported short interest (shares) 3,367,011
- Short interest (% of shares outstanding) 4.66%
- Prior settlement (shares) 2,814,458
- Reported change 19.63%
- Days to cover (reported) 9.46
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Biogen (BIIB)
- Eli Lilly (LLY)
- Eisai (ESAIY)
- Roche (RHHBY)
- ProMIS Neurosciences (PMN)
- Athira Pharma (ATHA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ABOS vs…
ACUMEN PHARMACEUTICALS INC is found in…
Frequently asked questions
What does ACUMEN PHARMACEUTICALS INC (ABOS) do?
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting amyloid-beta oligomers (AßOs), which are believed to be a primary driver of Alzheimer's disease pathology. The company's lead product candidate, sabirnetug (ACU193), is a humanized monoclonal antibody currently in Phase 2 clinical trials (ALTITUDE-AD) designed to selectively target and neutralize AßOs.
What sector is ACUMEN PHARMACEUTICALS INC (ABOS) in?
ACUMEN PHARMACEUTICALS INC (ABOS) is classified in the Health Care sector. Its industry is Alzheimer's disease / neurodegeneration therapeutics. It trades on NASDAQ.
Who are ACUMEN PHARMACEUTICALS INC's (ABOS) competitors?
Notable peers of ACUMEN PHARMACEUTICALS INC (ABOS) include Biogen, Eli Lilly, Eisai, Roche and ProMIS Neurosciences. This peer set is informational only — not financial advice.
Is ACUMEN PHARMACEUTICALS INC (ABOS) overbought or oversold right now?
ACUMEN PHARMACEUTICALS INC (ABOS) is currently in overbought territory (its 14-day RSI is 78, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ABOS come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.